News | November 08, 2013

Zevacor Molecular Awards IBA Contract to Build Only U.S. Commercial Cyclotron for Sr-82 Production

Cyclone 70 to stabilize U.S. supply of strontium 82/rubidium 82 generators for use in diagnosis of cardiovascular disease

cyclone 70 zevacor IBM nuclear imaging radiopharmaceuticals and tracers PET
November 8, 2013 — Zevacor Molecular, a healthcare firm that manufactures and distributes positron emissions tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A. (IBA).
 
The purchase of IBA’s Cyclone 70 is the first of several investments Zevacor is making to secure the future of nuclear medicine and molecular imaging. The 70 MeV Cyclotron is expected to be operational in the fall of 2016 and will help to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses. 
 
Strontium 82 (Sr-82) has a half-life of about 25 days, allowing it to be easily shipped to imaging facilities for about a month of use. It is shipped as a generator unit to produce rubidium 82 (Rb-82) at the point of imaging, since Rb-82 has a half-life of only 75 seconds. The isotope is primarily used for nuclear myocardial perfusion exams.
 
In addition to the cyclotron, Zevacor will also invest in significant infrastructure to create a state-of-the-art manufacturing facility to house the Cyclone 70 as well as other cyclotrons and manufacturing equipment. It expects to determine the location by the end of 2013.
 
“This is just the beginning,” said John Zehner, executive vice president and chief operating officer, Zevacor Molecular. “With strategic investments like the purchase of the Cyclone 70, Zevacor and our partners will help hospitals improve the diagnosis and treatment of cancer, cardiovascular disease and other critical illnesses. Our goal is to support the current needs of the nuclear medicine and molecular imaging community and assist in the growth and development of new diagnostics and therapeutics.”
 
The main focus of the first 70 MeV Cyclotron will be to commercially manufacture Sr-82 to ensure ample, stable, U.S.-based supply of Sr-82/Rb-82 generators for use in the diagnosis of cardiovascular disease. This important radiotracer has no current commercial supplier and only has U.S. and foreign-based supply from national labs.
 
Although the primary focus is the manufacture of Sr-82, the Cyclone 70 is capable of producing a wide variety of other radionuclides for both research and clinical applications. 
 
For more information: www.zevacor.com, www.iba-worldwide.com

Related Content

ScImage and Invia Partnership Announced
News | Cardiac PACS| September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging| September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging| September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers| August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Sponsored Content | Videos | Nuclear Imaging| August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Sponsored Content | Videos | Nuclear Imaging| August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
Overlay Init